Silexion Therapeutics Files 8-K for Reg FD Disclosure

TL;DR

**Silexion just dropped an 8-K with a Reg FD disclosure, so expect news that could move the stock.**

AI Summary

Silexion Therapeutics Corp filed an 8-K on March 24, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of material non-public information. This filing includes an exhibit, EX-99.1, which likely contains the details of this disclosure. For investors, this matters because Regulation FD ensures all investors receive important company news simultaneously, preventing insider trading and ensuring fair access to information that could impact the stock price.

Why It Matters

This filing signals that Silexion Therapeutics Corp is releasing important, previously non-public information to all investors, which could influence the stock's valuation.

Risk Assessment

Risk Level: low — The filing itself is a standard disclosure mechanism and doesn't inherently carry high risk, though the content of the disclosed information might.

Analyst Insight

A smart investor would review Exhibit 99.1 immediately to understand the specific material non-public information Silexion Therapeutics Corp is disclosing, as this information could impact the company's future prospects and stock price.

Key Players & Entities

• Silexion Therapeutics Corp (company) — the filer of the 8-K
• 0002022416 (company) — Silexion Therapeutics Corp's CIK
• 2026-03-24 (date) — the filing date and period of report
• Item 7.01 (null) — the specific item of the 8-K filing
• Regulation FD Disclosure (null) — the type of disclosure under Item 7.01
• EX-99.1 (null) — the exhibit containing the disclosure details

FAQ

Key Financial Figures

• $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
• $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma

Filing Documents

• zk2634889.htm (8-K) — 50KB
• exhibit_99-1.htm (EX-99.1) — 14KB
• image00001.jpg (GRAPHIC) — 3KB
• 0001178913-26-001615.txt ( ) — 242KB
• slxn-20260324.xsd (EX-101.SCH) — 5KB
• slxn-20260324_def.xml (EX-101.DEF) — 18KB
• slxn-20260324_lab.xml (EX-101.LAB) — 27KB
• slxn-20260324_pre.xml (EX-101.PRE) — 20KB
• zk2634889_htm.xml (XML) — 6KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 24, 2026, Silexion Therapeutics Corp issued a press release entitled " Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer ". A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this " Form 8-K ") and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated March 24, 2026 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: March 24, 2026 /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR